{"id":6696,"date":"2020-04-25T19:37:10","date_gmt":"2020-04-25T19:37:10","guid":{"rendered":"https:\/\/zuviuslifesciences.in\/old\/?post_type=product&p=6696"},"modified":"2020-07-21T06:28:49","modified_gmt":"2020-07-21T06:28:49","slug":"zuvitop-inj","status":"publish","type":"product","link":"https:\/\/zuviuslifesciences.in\/old\/product\/zuvitop-inj\/","title":{"rendered":"Zuvitop Inj"},"content":{"rendered":"

[vc_row][vc_column][vc_tta_tour color=”peacoc” active_section=”1″][vc_tta_section title=”Description” tab_id=”1584624217032-a15849ed-97bb”][vc_column_text]<\/p>\n

\n
\n
\n

Zuvitop-100 (etoposide Injection, IP) is a semisynthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. It is 4′-demethylepipodophyllotoxin 9-[4,6-0-(R)- ethylidence – B-D- glucopyranoside]. It is very soluble in methanol and chloroform, slightly soluble in ethanol, and sparingly soluble in water and ether. It is made more miscible with water by means of organic solvents. It has a molecular weight of 588.58 and a molecular formula of C29 H32 O13.<\/p>\n

The Structural formula is :<\/strong><\/p>\n

\"Zuvitop-100\"<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/div>\n

[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Composition” tab_id=”1593242897143-c04823a2-22fb”][vc_column_text]<\/p>\n

\n
\n

Each ml contains:<\/p>\n

Etoposide \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 IP\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20 mg<\/p>\n

Citric Acid\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 IP\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 2 mg<\/p>\n

Polysorbate 80\u00a0 IP\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80 mg<\/p>\n

Polyethylene glycol 300IP\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 650 mg<\/p>\n

Benzoyl alcoholIP\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30 mg<\/p>\n

Ethyl alcohol\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 IP\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30.5% v\/v<\/p>\n<\/div>\n<\/div>\n

<\/div>\n

[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Mechanism of Action \/ Pharmcodynamics” tab_id=”1584624217050-ebb8ae5e-43a6″][vc_column_text][\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Pharmacokinetics” tab_id=”1584624459062-96fb7e5b-0e23″][vc_column_text]<\/p>\n

    \n
  • On intravenous \u00a0administration, the disposition of etoposide is best described as a biphasic \u00a0process with a distribution half-life of about 1.5 hours and terminal \u00a0elimination half-life ranging from 4 to 11 hours. Total body clearance values \u00a0range from 33 to 48 mL\/min or 16 to 36 mL\/min\/m2 and, like the terminal \u00a0elimination half-life, are independent of dose over a range of 100 to 600 \u00a0mg\/m2. Over the same dose range, the areas under the plasma concentration vs. \u00a0time curves (AUC) and the maximum plasma concentration (Cmax) values increase \u00a0linearly with dose. Etoposide does not accumulate in the plasma following daily \u00a0administration of 100 mg\/m2 for 4 or 5 days.<\/li>\n
  • The mean volumes of \u00a0distribution at steady state fall in the range of 18 to 29 liters or 7 to 17 \u00a0L\/m2. Etoposide enters the CSF poorly. Although it is detectable in CSF and \u00a0intracerebral tumors, the concentrations are lower than in extracerebral tumors \u00a0and in plasma. Etoposide concentrations are higher in normal lung than in lung \u00a0metastases and are similar in primary tumors and normal tissues of the \u00a0myometrium. In vitro, etoposide is highly protein bound (97%) to human plasma \u00a0proteins. An inverse relationship between plasma albumin levels and etoposide \u00a0renal clearance is found in children. In a study determining the effect of \u00a0other therapeutic agents on the in vitro binding of carbon-14 labeled etoposide \u00a0to human serum proteins, only phenylbutazone, sodium salicylate, and aspirin \u00a0displaced protein-bound etoposide at concentrations achieved in vivo.<\/li>\n
  • Etoposide binding \u00a0ratio correlates directly with serum albumin in patients with cancer and in \u00a0normal volunteers. The unbound fraction of etoposide significantly correlated \u00a0with bilirubin in a population of cancer patients. Data have suggested a \u00a0significant Inverse correlation between serum albumin concentration and free \u00a0fraction of etoposide.<\/li>\n
  • After intravenous \u00a0administration of 14C-etoposide (100 to 124 mg\/m2), mean recovery of \u00a0radioactivity in the urine was 56% of the dose at 120 hours, 45% of which was \u00a0excreted as etoposide: fecal recovery of radioactivity was 44% of the dose at \u00a0120 hours.<\/li>\n
  • In children, \u00a0approximately 55% of the dose is excreted in the urine as etoposide in 24 \u00a0hours. The mean renal clearance of etoposide is 7 to 10 mL\/min\/m2 or about 35% \u00a0of the total body clearance over a dose range of 80 to 600 mg\/m2. Etoposide, \u00a0therefore, is cleared by both renal and nonrenal processes, i.e., metabolism \u00a0and biliary excretion. The effect of renal disease on plasma etoposide \u00a0clearance is not known.<\/li>\n
  • Biliary excretion \u00a0of unchanged drug and\/or metabolites is an important route of etoposide \u00a0elimination as fecal recovery of radioactivity is 44% of the intravenous dose. \u00a0The hydroxy acid metabolite [4\u2019-demethylepipodophyllic \u00a0acid-9-(4,6-O-(R)-ethylidene-\u03b2-D-glucopyranoside)], formed by opening of the \u00a0lactone ring, is found in the urine of adults and children. It is also present \u00a0in human plasma, presumably as the trans isomer. Glucuronide and\/or sulfate \u00a0conjugates of etoposide are also excreted in human urine. Only 8% or less of an \u00a0intravenous dose is excreted in the urine as radiolabeled metabolites of \u00a014C-etoposide. In addition, O-demethylation of the dimethoxyphenol ring occurs \u00a0through the CYP450 3A4 isoenzyme pathway to produce the corresponding catechol.<\/li>\n
  • After intravenous \u00a0infusion, the Cmax and AUC values exhibit marked intra- and inter-subject \u00a0variability.<\/li>\n
  • There is no \u00a0evidence of a first-pass effect for etoposide. For example, no correlation \u00a0exists between the absolute oral bioavailability of etoposide capsules and \u00a0nonrenal clearance. No evidence exists for any other differences in etoposide \u00a0metabolism and excretion after administration of oral capsules as compared to \u00a0intravenous infusion.<\/li>\n
  • In adults, the \u00a0total body clearance of etoposide is correlated with creatinine clearance, \u00a0serum albumin concentration, and nonrenal clearance. Patients with impaired \u00a0renal function receiving etoposide have exhibited reduced total body clearance, \u00a0increased AUC and a lower volume of distribution at steady state. Use of \u00a0cisplatin therapy is associated with reduced total body clearance. In children, \u00a0elevated serum SGPT levels are associated with reduced drug total body \u00a0clearance. Prior use of cisplatin may also result in a decrease of etoposide \u00a0total body clearance in children.<\/li>\n
  • Although some minor \u00a0differences in pharmacokinetic parameters between age and gender have been \u00a0observed, these differences were not considered clinically significant.<\/li>\n<\/ul>\n

    [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Indications” tab_id=”1584624839401-59481bbb-bdc7″][vc_column_text]<\/p>\n

    \n
    \n
    \n
    \n
      \n
    • Etoposide Injection is \u00a0indicated in the management of the following neoplasms.<\/li>\n
    • Small cell lung cancer, \u00a0malignant lymphomas<\/li>\n
    • Acute leukemia\u2019s… Testicular \u00a0tumors.<\/li>\n
    • Bladder Cancer. Trophoblastic \u00a0diseases<\/li>\n
    • Etoposide Injection are \u00a0indicated in the management of the following neoplasms.<\/li>\n
    • Small cell lung cancer. \u00a0Malignant lymphomas.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
      <\/div>\n

      [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Dosage & Administration” tab_id=”1584625017135-3ffdd9c5-1bd6″][vc_column_text][\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Warnings” tab_id=”1587843996866-9298d292-1b3f”][vc_column_text][\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Precautions” tab_id=”1587844037709-11565774-3e33″][vc_column_text][\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Adverse Reactions (Side Effects)” tab_id=”1587844082724-87af7183-45e5″][vc_column_text]<\/p>\n

      \n
      \n
      \n

      Hematologic toxicity: Myelosuppression is dose-related and dose-limiting with granulocyte nadirs occurring 7 to 14 days after drug administration and platelet nadirs occurring 9 to 16 days after drug administration. Bone marrow recovery is usually complete by day 20 and no cumulative toxicity has been reported.<\/p>\n

      Gastrointestinal Toxicity: Nausea and vomiting are the major gastrointestinal toxicities. The severity of such nausea and vomiting is generally mild to moderate with treatment discontinuation required in 1% of patients. Nausea and vomiting can usually be controlled with standard antiemetic therapy.<\/p>\n

      Hypotension: Transient hypotension following rapid intravenous administration has been reported in 1% to 2% of patients. It has not been associated with cardiac toxicity or electrocardiographic changes. No delayed hypotension has been noted. To prevent this rare occurrence it is recommended that Etoposide be administered by slow intravenous infusion over a 30 to 60 minute period. If hypotension occurs, it usually responds to cessation of the infusion and administration of fluids or other supportive therapy as appropriate. When restarting the infusion, slower administration rate should be used.<\/p>\n

      Allergic reactions: Anaphylactic – like reactions characterized by chills, fever, tachycardia, bronchospasm, dyspnea and hypotension have been reported to occur in 0.7 % to 2% of patients receiving intravenous Etoposide. These reactions have usually responded promptly to the cessation of the infusion and administration of presser agents, corticosteroids, antihistamines or volume expanders as appropriate. One fatal acute reaction associated with bronchospasm has been reported. Hypertension and flushing have also been reported. Blood pressure usually normalizes within a few hours after cessation of the infusion.<\/p>\n

      Alopecia: Reversible alopecia, sometimes progressing to total baldness was observed in upto 66% of patients.<\/p>\n

      Other toxicities: The following adverse reactions have been infrequently reported: rash, fever, pigmentation, pruritus, abdominal pain, constipation, dysphagia, transient cortical blindness and a single report of radiation recall dermatitis.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

      <\/div>\n

      [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Drug Interactions” tab_id=”1587844141637-11ae9e7f-1edf”][vc_column_text][\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Overdose & Contradiction” tab_id=”1587844181062-3e576ac3-018a”][vc_column_text]<\/p>\n

      \n
      \n
      \n

      OVER DOSAGE:<\/strong><\/p>\n

      No proven antidotes have been established for Etoposide overdosage.<\/p>\n

      CONTRAINDICATIONS:<\/strong><\/p>\n

      Etoposide is contraindicated in patients who have demonstrated a previous Hypersensitivity to it.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

      <\/div>\n

      [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Storage” tab_id=”1587844240644-f334ccea-fef2″][vc_column_text][\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Presentation” tab_id=”1587844292609-c417b47d-2de1″][vc_column_text][\/vc_column_text][\/vc_tta_section][\/vc_tta_tour][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

      \n
      \n
      \n

      \u00a0Etoposide\u00a0 Inj –\u00a0 100MG<\/h3>\n
      \n
      \n
      \n
      \n
        \n
      • Etoposide Injection is indicated in the management of the following neoplasms.<\/li>\n
      • Small cell lung cancer, \u00a0malignant lymphomas<\/li>\n
      • Acute leukemia\u2019s… Testicular tumors.<\/li>\n
      • Bladder Cancer. Trophoblastic \u00a0diseases<\/li>\n
      • Etoposide Injection are indicated in the management of the following neoplasms.<\/li>\n
      • Small cell lung cancer. \u00a0Malignant lymphomas.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
        <\/div>\n<\/div>\n<\/div>\n<\/div>\n
        <\/div>\n","protected":false},"featured_media":7824,"template":"","meta":{"spay_email":""},"product_cat":[66,67],"product_tag":[175,174],"jetpack-related-posts":[{"id":6760,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/zuvitop-caps\/","url_meta":{"origin":6696,"position":0},"title":"Zuvitop Caps","date":"April 27, 2020","format":false,"excerpt":"Etoposide caps - 100MG Zuvitop-50 capsules are indicated in the management of the following neoplasms: Small Cell Lung Cancer Malignant Lymphomas","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/Zuvitop-Group_1000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":6701,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/z-blastin-inj\/","url_meta":{"origin":6696,"position":1},"title":"Z-Blastin Inj","date":"April 26, 2020","format":false,"excerpt":"Vinblastine Inj - 10MG \u00a0","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/image-10-3.jpg?fit=615%2C385&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":6717,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/zolon-inj\/","url_meta":{"origin":6696,"position":2},"title":"Zolon Inj","date":"April 27, 2020","format":false,"excerpt":"Oxaliplatin Inj - 150MG 100MG 50MG Oxaliplatin is indicated in the treatment of metastatic colorectal cancers after the failure of treatment of fluoropyrimidines, alone by monochemotherapy or along with fluoropyrimidines. \u00a0","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/Zolon-Group-2_1000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":7633,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/zitomycin-inj\/","url_meta":{"origin":6696,"position":3},"title":"Zitomycin Inj","date":"July 15, 2020","format":false,"excerpt":"Coming Soon","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/07\/Zitomyciin-Group_1_1000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":7625,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/dactinoz-inj\/","url_meta":{"origin":6696,"position":4},"title":"Dactinoz Inj","date":"July 15, 2020","format":false,"excerpt":"[vc_row][vc_column][vc_tta_tour color=\"peacoc\" active_section=\"1\"][vc_tta_section title=\"Description\" tab_id=\"1584624217032-a15849ed-97bb\"][vc_column_text] Coming Soon [\/vc_column_text][\/vc_tta_section][vc_tta_section title=\"Composition\" tab_id=\"1593256673750-3638ffc1-7c86\"][\/vc_tta_section][vc_tta_section title=\"Mechanism of Action \/ Pharmcodynamics\" tab_id=\"1584624217050-ebb8ae5e-43a6\"][\/vc_tta_section][vc_tta_section title=\"Pharmacokinetics\" tab_id=\"1584624459062-96fb7e5b-0e23\"][\/vc_tta_section][vc_tta_section title=\"Indications\" tab_id=\"1584624839401-59481bbb-bdc7\"][\/vc_tta_section][vc_tta_section title=\"Dosage & Administration\" tab_id=\"1584625017135-3ffdd9c5-1bd6\"][\/vc_tta_section][vc_tta_section title=\"Warnings\" tab_id=\"1587817939178-adf17690-852e\"][\/vc_tta_section][vc_tta_section title=\"Precautions\" tab_id=\"1587818014990-5d94836a-de8b\"][\/vc_tta_section][vc_tta_section title=\"Adverse Reactions (Side Effects)\" tab_id=\"1587818095762-1b87ff2a-b8c5\"][\/vc_tta_section][vc_tta_section title=\"Drug Interactions\" tab_id=\"1587818155761-d90498d3-cbef\"][\/vc_tta_section][vc_tta_section title=\"Overdose & Contradiction\" tab_id=\"1587818245984-4b49fce1-2eee\"][\/vc_tta_section][vc_tta_section title=\"Storage\" tab_id=\"1587818382766-3a4f2803-90d0\"][\/vc_tta_section][vc_tta_section title=\"Presentation\" tab_id=\"1587818494097-bca75969-4f2d\"][\/vc_tta_section][\/vc_tta_tour][\/vc_column][\/vc_row]","rel":"","context":"Similar post","img":{"alt_text":"Dactinoz-0.5mg_1_1000 x 1000px","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/07\/Dactinoz-0.5mg_1_1000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":7629,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/zadaunor-inj\/","url_meta":{"origin":6696,"position":5},"title":"Zedaunor Inj","date":"July 15, 2020","format":false,"excerpt":"[vc_row][vc_column][vc_tta_tour color=\"peacoc\" active_section=\"1\"][vc_tta_section title=\"Description\" tab_id=\"1584624217032-a15849ed-97bb\"][vc_column_text] Coming Soon [\/vc_column_text][\/vc_tta_section][vc_tta_section title=\"Composition\" tab_id=\"1593256673750-3638ffc1-7c86\"][\/vc_tta_section][vc_tta_section title=\"Mechanism of Action \/ Pharmcodynamics\" tab_id=\"1584624217050-ebb8ae5e-43a6\"][\/vc_tta_section][vc_tta_section title=\"Pharmacokinetics\" tab_id=\"1584624459062-96fb7e5b-0e23\"][\/vc_tta_section][vc_tta_section title=\"Indications\" tab_id=\"1584624839401-59481bbb-bdc7\"][\/vc_tta_section][vc_tta_section title=\"Dosage & Administration\" tab_id=\"1584625017135-3ffdd9c5-1bd6\"][\/vc_tta_section][vc_tta_section title=\"Warnings\" tab_id=\"1587817939178-adf17690-852e\"][\/vc_tta_section][vc_tta_section title=\"Precautions\" tab_id=\"1587818014990-5d94836a-de8b\"][\/vc_tta_section][vc_tta_section title=\"Adverse Reactions (Side Effects)\" tab_id=\"1587818095762-1b87ff2a-b8c5\"][\/vc_tta_section][vc_tta_section title=\"Drug Interactions\" tab_id=\"1587818155761-d90498d3-cbef\"][\/vc_tta_section][vc_tta_section title=\"Overdose & Contradiction\" tab_id=\"1587818245984-4b49fce1-2eee\"][\/vc_tta_section][vc_tta_section title=\"Storage\" tab_id=\"1587818382766-3a4f2803-90d0\"][\/vc_tta_section][vc_tta_section title=\"Presentation\" tab_id=\"1587818494097-bca75969-4f2d\"][\/vc_tta_section][\/vc_tta_tour][\/vc_column][\/vc_row]","rel":"","context":"Similar post","img":{"alt_text":"Zedaunor 20mg_1_1000 x 1000px","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/07\/Zedaunor-20mg_1_1000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]}],"_links":{"self":[{"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/product\/6696"}],"collection":[{"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/media\/7824"}],"wp:attachment":[{"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/media?parent=6696"}],"wp:term":[{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/product_cat?post=6696"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/product_tag?post=6696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}